



NEWS RELEASE

Teijin, J-TEC and Resilience Form Business Alliance to Spur Development of New Regenerative Medicine Technologies

Tokyo, Japan, April 21, 2023 --- <u>Teijin Limited</u> and <u>Japan Tissue Engineering Co., Ltd.</u> (J-TEC) announced today that they have entered into a Letter of Intent for a global strategic collaboration with <u>Resilience US, Inc. (Resilience)</u> to enhance contract development and manufacturing organization (CDMO) capabilities for cell and gene therapies, including regenerative medicines, to customers in North America and Asia-Pacific (APAC).

Teijin, J-TEC and Resilience intend to mutually support and facilitate the expansion of their clients' businesses to the respective regions. Resilience would serve as one of the preferred suppliers and manufacturers to Teijin and J-TEC's customers for North America-based process and analytical development (PAD) and biomanufacturing and refer Teijin and J-TEC for APAC-based PAD and biomanufacturing. In addition, Resilience would serve as one of the preferred suppliers of viral vectors for use in the development and manufacture of cell and gene therapy products.

Together, the three companies aim to accelerate development and production of new manufacturing technologies related to cell and gene therapies, and regenerative medicines. Additionally, the companies will discuss a cross-licensing arrangement to enable each party to use the other party's proprietary manufacturing platforms and related technology in their home jurisdiction, Japan or North America, as applicable. The development of preferred clinical trial and regulatory pathways for the companies' customers is also under discussion. The development of preferred clinical trial and regulatory pathways for the companies' customers in Japan and North America is also under discussion.

"Teijin, J-TEC, and Resilience are contributing to the provision of innovative medical care through manufacturing," said Takayuki Nakano, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited. "Teijin and J-TEC will invest in facilities and human resources to meet customer needs, with a goal of JPY 20 billion in regenerative medicine sales of the Teijin Group by FY 2030, and this collaboration will encourage to achieve this goal."


"We are excited to collaborate with Teijin and J-TEC to envision a future where we could bring Resilience's manufacturing capabilities to the Asia-Pacific region," said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. "Combining Teijin's engineering expertise with our organization's capabilities in biopharmaceutical manufacturing and medical innovation can potentially provide customers with transpacific manufacturing solutions that ensure therapies can be made quickly, safely, and at scale."

Demand for CDMO services in cell and gene therapies, including regenerative medicines, is rising due to heightened technical levels in manufacturing and specialization in manufacturing and development functions. Demand for regenerative medicine market is rapidly growing and is estimated to exceed JPY 850 billion in 2030 in Japan. This trend

is assumed to result in increase of regenerative medicine products originated outside Japan in the Japanese market, making a system that connects development demand between Japan and outside Japan vital.

Teijin and J-TEC, the Teijin Group's core regenerative-medicine business, already have experience collaborating to support customers. In September 2022 they established a one-stop R&D system with the <u>National Cancer Center Japan</u> and <u>Mitsui Fudosan Co., Ltd.</u> in <u>Kashiwanoha Smart City</u>, a life science business park near Tokyo.







Teijin's new CMO base (Iwakuni, Japan) scheduled to start operation in 2024

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement "Human Chemistry, Human Solutions," Teijin aims to be a company that supports the society of the future. The group comprises some 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2022. Please visit www.teijin.com

About J-TEC

J-TEC (TSE: 7774) is a maker of regenerative medical products whose corporate vision is "creating a future for regenerative medicine," and has been a member of the Teijin Group since March 2021. As Japan's top runner in regenerative medicine, J-TEC obtained marketing approval for autologous cultured epidermis "JACE", Japan's first regenerative medical product, in October of 2007, and began marketing the product in January of 2009. J-TEC then went on to obtain marketing approval for Autologous Cultured Cartilage "JACC" in July of 2012, for Autologous Cultured Corneal Epithelium

"Nepic" in March of 2020, and for Autologous Cultured Oral Mucosal Epithelium "Ocural" in June 2021, and for Autologous Cultured Epidermis Maintaining Melanocytes "JACEMIN" in March 2023. Of the 19 regenerative medical products that have been approved in Japan, five are J-TEC products. By making the most of the experience and knowhow cultivated through these achievements, J-TEC is engaging in contract development of regenerative medical products, consulting, and contract manufacture of specific cell-processed products.

Please visit www.jpte.co.jp/en/

About Resilience

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell therapy, and gene therapy modalities). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients' lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com/ and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.

The Teijin Group Press Contacts

Investor and Public Relations Department Teijin Limited +81 (0)3 3506 4055 pr@teijin.co.jp

Corporate Management Department Japan Tissue Engineering Co., Ltd. +81 (0) 533 66 2020 itec-info@jpte.co.jp

Resilience Media Contact:

Michele Roberts
Head of Communications
+16092848213
Michele.roberts@Resilience.com

Resilience Investor Contact:

Tatjana Heller
Head of Investor Relations and Analytics
+17745734579
Tatjana.heller@Resilience.com